Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Effects on CD34+ Cells in T2D with Renal Impairment
NCT02467478Phase 4Completed
- Sponsor
- George Washington University
- Start
- Apr 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of linagliptin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by George Washington University. Started Apr 2015; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02467478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467478.